CRANBURY, N.J. & SHANGHAI--(BUSINESS WIRE)--Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, announces that the China National Medical Products Administration (NMPA) has cleared the company’s investigational new drug application (IND) for AC0176 for the treatment of patients with metastatic Castration Resistant Prostate Cancer (mCRPC). AC0176 is an orally bioavailable chimeric degrader molecule...

BROOKLYN, N.Y.--(BUSINESS WIRE)--Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AC0176 for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) with disease progression on or after treatment with androgen receptor signaling inhibitors. AC0176...

– Chimeric Degrader With a Differentiated Mechanism of Action vs. Androgen Receptor Inhibitors –

– Broad AR Mutant Coverage Designed to Overcome Resistance to Current AR-Targeted Therapies –

BROOKLYN, N.Y.--(BUSINESS WIRE)--Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery, today announced the dosing of the first patient in a Phase 1 study of AC0176, an...

Accutar Biotech Inc., a biotechnology company specializing in artificial intelligence (AI)-empowered drug discovery, today announced that Dr. Alexander Varshavsky, a world leader in the ubiquitination system, has joined the Scientific Advisory Board (SAB) of the company to advise on novel E3 ligase discovery programs.

“It is our great honor and privilege to have Dr. Varshavsky join our SAB”, said Jie Fan, PhD, founder and CEO...

BROOKLYN, N.Y.--(BUSINESS WIRE)--Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug application (IND) for AC0176 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). AC0176 is an orally bioavailable, chimeric degrader molecule designed to target and degrade androgen receptor (AR)...

– Differentiated Mechanism of Action by Chimeric Degrader vs. Fulvestrant and Novel SERDs –

– ERα Wildtype & Mutant Coverage to Overcome Resistance –

– Blood-Brain Barrier Penetration to Address Brain Metastases –

BROOKLYN, N.Y.--(BUSINESS WIRE)--Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery, today announced the dose administration for the first patient in a Phase...

BROOKLYN, N.Y.--(BUSINESS WIRE)--Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug application (IND) for AC0682 for the treatment of patients with estrogen receptor (ER)-positive breast cancers. AC0682 is an orally bioavailable, chimeric degrader molecule designed to target and degrade ERα protein with high...

Accutar Biotech Inc., a technology company specialized in AI guided drug discovery, announced Dr. Carlos Garcia-Echeverria serves as CEO advisor to support the company’s internal drug discovery pipeline.

“We are honored to have Dr. Garcia-Echeverria’s insights to develop best-in-class and first-in-class medicines for unmet medical needs,” said Jie Fan, PhD, founder and CEO of Accutar, “Carlos sets a high bar for our AI guided...

Accutar Biotech Inc., a technology company pioneering AI guided drug discovery to bring broader benefits for patients, announced Dr. Pasi A. Jänne joins scientific advisory board to support development of the company’s pipeline drugs in lung cancer.

“It is our honor to have world esteemed leaders like Dr. Pasi A. Jänne to advise us to develop precision medicines for unmet medical needs in the...

Accutar Biotech has recently completed a new round of funding from Yunfeng Capital, Coatue, and 3W Healthcare Fund, in addition to the previous investments from ZhenFund, IDG Capital, YITU Technology, Primavera Capital Group, CDH Investments, and other institutional investors. Accumulatively, Accutar Biotech has now raised over US$100 million to support the advancement of the world-leading artificial intelligence (AI)-empowered platform and the expansion of our...

Based on round 1 submission results, the Accutar Biotech team ranked number 1 of over 300 participants in the IDG-DREAM Drug-Kinase Binding Prediction Challenge.

Accutar Biotech CEO, Dr. Jie Fan, was invited to present at Amgen’s artificial intelligence conference.

Figure: Side chain flexible docking model (in green) enables the chimera design of two ligand fragments (in yellow and pink). A bisubstrate nicotinamide N-methyltransferase (NNMT) inhibitor was developed with the aid of Accutar Biotech’s platform recently. The binding pose of the designed inhibitor with human recombinant NNMT was predicted by Accutar Biotech’s side chain flexible docking method. The docking result was further validated...

Using a deep neural network architecture without physics-based assumptions, Accutar Biotech has demonstrated that side chain conformation prediction accuracy can be improved by more than 25%, especially for aromatic residues compared with current standard methods. Read more